What is Psilocybin Research?
Psilocybin Research is an independent publication that tracks the science, cost and legal status of psilocybin in the United States. It maintains the legal status of psilocybin in all 51 states and the District of Columbia, checked against statutes rather than other trackers; it reports clinical evidence with its limitations attached, including when those limitations are unflattering to psilocybin; and it corrects claims that circulate unchallenged in the field. It is not owned by or affiliated with any clinic, retreat, drug developer or advocacy organization.
Masthead
The work
Each one is a dataset rather than an article, which is why they carry review dates and why correcting them is a standing obligation rather than an occasional event.
51jurisdictions
Every state and DC, each entry citing the statute, ballot measure or agency page behind it. Right now 2 run legal supervised access, 1 are building a program, and 7 have cities that deprioritized enforcement without changing any law — a distinction that decides cases.
Open the tracker133open trials
Effect sizes, sample sizes, whether there was a control group, whether the primary endpoint was met — including where the answer is unflattering to psilocybin. The registry flags the medication washout that disqualifies most people who apply.
What the research shows19claims corrected
Three states are widely listed as decriminalized that are not. A famous depression trial is routinely described as showing something its authors said it did not show. Each entry names the claim, the correction, and the source that settles it.
The corrections ledgerMethod
Every claim here is meant to be checkable by a reader who does not trust us, which is the correct starting position.
AI is used for research assistance, drafting and code. Every factual claim is verified against its primary source by a person before it goes live, and a person is accountable for every page. No AI has a byline here.
Three limits are worth stating plainly, because they are the ones readers most often arrive hoping we will break. Dosing protocols and taper schedules are outside what this publication prints — for psilocybin and for psychiatric medication alike. A prescription is a conversation with a prescriber, so we will tell you what a study found and leave the decision where it belongs. And preliminary research stays labeled as research: a twenty-person uncontrolled pilot is news, rather than something to act on.
The rules in full are on our editorial standards page, which also covers what we owe the tradition this medicine came from.
We will make mistakes, and reader corrections are the cheapest quality control there is. A link to the statute or the paper is the fastest route to a fix.